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1. RATIONALE OF 
THE NATIONAL 
GUIDELINE
T h e  e p i d e m i o l o g y  o f 
Clostridioides difficile (CD) 
infection (CDI) has become 
more worrying in the past years, 
with a prevalence reaching 
5 . 4 %  i n  a  mu l t i n at i o n a l 
European Centre for Disease 
Prevention and Control (ECDC) 
coordinated point prevalence 
survey, representing 48% of the 
gastrointestinal (GI) hospital 
care associated infections. The 
same study outlines an increased 
prevalence compared to the 
previous studies and also reports 
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ABSTRACT
Fecal microbiota transplantation involves the infusion of intestinal microorganisms via the transfer of a stool 
from a healthy individual into a diseased individual, with the intent of restoring normal intestinal flora. Fecal 
transplant is proposed for the treatment of refractory Clostridioides difficile infection. At present, recurrent 
Clostridioides difficile infection is the only indication supported by solid scientific evidence. Regulations by 
healthcare authorities vary among different countries. Considering that Romania does not have an available 
national guideline to offer standardization, this paper aimed to create a national fecal microbiota transplantation 
guideline concerning indications, techniques and donor screening, developed by international and local 
scientific working groups.
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rezistent enterococci; WG: working group. 
an increase in polymerase chain reaction (PCR) ribotype 027, 
associated with worse patient outcome [1]. 
Moreover, the EUCLID study reported the prevalence of 
ribotype 027 strains to be among the highest in Europe in 
Romania [2] and a recent study performed in tertiary centers 
from 6 cities in different areas from Romania identified a 
mean prevalence of 5.2 cases per 10,000 patient days, with 
the highest prevalence of PCR ribotype 027 of 82.6%, values 
which are higher compared to the one previously reported [3]. 
Specific patients’ category are at a higher risk for CDI, with a 
recent study performed in two tertiary centers in Romania 
highlighting a 27.6% rate of CDI in octogenarian patients 
[4]. Considering this epidemiological data, it is important to 
expand the therapeutic options, especially if we further take 
into account that 15.2% of patients experience recurrence 
within 8 weeks from the initial episode of CDI, while for 
patients with previous recurrences, the risk further increases 
up to 40.6% [5, 6]. Moreover, CDI is associated with high 
management costs, particularly in recurrent cases [7]. 
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In this context, the use of fecal microbiota obtained 
from healthy individuals was shown to represent an effective 
treatment option for recurrent and refractory CDI. A recent 
meta-analysis evaluated the efficacy of fecal microbiota 
transplantation (FMT) for both recurrent and refractory CDI, 
highlighting the effectiveness of this treatment option for both 
these situations and suggested the superiority of the lower 
gastrointestinal delivery in obtaining good outcome. However, 
both routes of FMT delivery resulted in over 85% effectiveness 
[8]. In Romania, isolated cases successfully managed using 
FMT [9] and one prospective study comprising 30 patients 
with recurrent CDI [10] was reported. Moreover, a recent 
study performed in one tertiary center in Romania revealed 
some aspects regarding FMT perception among medical 
students that require improvement [11]; consequently, better 
knowledge on this procedure needs to be promoted among 
Romanian practitioners.
Considering that Romania does not have an available 
national guideline to offer standardization and foster the 
implementation of the method, this may lead to impairment 
of the efficacy and safety of this method and could also 
lead to medico legal issues. Despite strong evidence and 
recommendation of implementing FMT centers for CDI, 
following the 2017 European Consensus covering this issue 
[12], in many European countries there is no national guideline 
to support implementation of this therapeutic option. 
Consequently, our aim was to create a national guideline 
for FMT in Romania, adapting the currently available guideline 
of the British Society of Gastroenterology and Healthcare 
Infection Society Guideline [13], the recent Consensus 
report of the UEG working group on stool banking [14],  and 
following the recommendations of the European Consensus 
on FMT [12] in clinical practice, taking into account the local 
conditions and also the need to adapt FMT practice in the 
context of COVID-19 pandemic [15].  Moreover, following 
this initiative, stool banking can be consequently developed 
and the extension and adaptation of FMT for pediatric use 
in local conditions could also be established. Therefore, these 
would represent important steps towards improving healthcare 
in Romania, contributing to minimizing disparities between 
health care systems in Eastern Europe, compared to Western 
European countries. Hopefully, the implementation of FMT 
will lead to reducing mortality associated with CDI and also to 
reducing health care costs related to its management. 
2. DEFINITIONS
Clostridioides difficile infection is defined as diarrheal 
stools or toxic megacolon and positive CD toxin A and/or B 
in stools or pseudomembranous colitis revealed by lower GI 
endoscopy; or colonic histopathology characteristic of CD 
infection (with or without diarrhea) on a specimen obtained 
during endoscopy, colectomy or autopsy [16].
Community-associated CDI is defined as the onset of 
CDI outside a healthcare facility or within 48 hours following 
admission to a healthcare facility without contact from a 
healthcare facility within the previous 12 weeks [16, 17].
Healthcare-associated CDI is defined as CDI with onset 
of symptoms: on day three or later, following admission to 
hospital or in the community within four weeks of discharge 
from a healthcare facility [17].
Clostridioides difficile colitis is characterized by several 
endoscopic findings such as bowel wall edema, erythema, 
friability, inflammation and pseudomembranes (raised 
yellowish or white plaques up to 2 cm in diameter over the 
colonic mucosa) which are highly suggestive for CDI [18]. 
Clostridioides difficile colonization is defined as the 
detection of the CD toxins in the absence of CDI symptoms 
[19].
Non-severe CDI is defined as at least 3 diarrhea stools 
(loose or watery) per day for 2 or more consecutive days, as 
the only symptom [19].
Severe CDI is characterized as an elevation in serum 
creatinine >1.5 times above the patient‘s normal levels, white 
blood cell count ≥15,000 cells/μL, or serum albumin <1.5 g/dL 
within 2 weeks from symptom onset [20]. The severity of colitis 
can be guided following the presence of ongoing abdominal 
pain, fever >38°C or white blood cell count >15,000 cells/μL 
despite oral vancomycin at a dose of 500 mg four times daily 
for at least 5 days [21].
Recurrent CDI (rCDI) is defined as diarrheal stools with a 
positive laboratory test after the end of treatment more than 2 
weeks and less than 8 weeks following the onset of a previous 
episode [13, 16].
Refractory CDI is defined as lack of response to medication 
after 5 days or more of treatment [14]. 
Fecal microbiota transplantation is defined as the transfer 
of stool’s biological material containing a community of 
microorganisms from a human donor to a human recipient 
with the aim of modifying the microbiota of the recipient [22]. 
3. METHODOLOGY FOR GUIDELINE 
DEVELOPMENT 
The process of developing the national guideline aimed 
at shaping evidence-based recommendations for the use of 
FMT in clinical practice, adapting them to the current local 
conditions in Romania. 
The guideline development process included the following 
steps: selection of the expert panel and members and calls for 
establishing the working group (WG), identification of main 
topics and generation of WG, development of statements 
according to the currently available evidence [12, 13, 23], 
review and adjustment of statements through online meetings 
and feedback after each session in order to release the final 
version of statements.
Original studies (prospective randomized, double-blinded, 
placebo-controlled studies) were included for the development 
of the guideline. In the absence of such studies, the evidence 
of lower quality was considered, including observational 
and retrospective studies or case series, as well as systematic 
reviews and meta-analyses. The data sources were found 
in the following electronic databases: PubMed, Scopus, 
ScienceDirect, Cochrane Library and Google Scholar, as well 
as recommendation statements and guidelines published on 
the websites of international scientific societies. The literature 
review and analysis were limited to articles published in either 
English or Romanian. 
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A total number of 6 experts from 4 European countries 
constituted the experts’ panel and 9 members constituted the 
WG from Romania.
The quality of evidence and strength of recommendation 
for each statement were determined according to the 
Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) system [24]. Definition of the strength of 
recommendation and the quality of the published evidence are 
detailed in Supplementary file (Supplementary Tables I and II).
Initial statements were edited after the first voting session 
and discussed during a second online meeting. For each 
statement, consensus members were requested to rate their 
level of agreement, among the following: (1) agree strongly; 
(2) agree with minor reservation; (3) agree with major 
reservation; (4) disagree with major reservation; (5) disagree 
with minor reservation; (6) disagree strongly. If the rating was 
other than ‘agree strongly’ respondents were requested to add 
some comments to explain their reservation/disagreement, 
and how to improve the statement. For each statement, the 
pre-established threshold was reached when the overall result 
was ≥80%, with the experts agreeing either strongly or with 
reservation. All statements not reaching 80% of agreement were 
revised and discussed during online meeting and following 
feedback. 
The second version of the statements was sent to all 
members of the working group for the second round of 
feedback. The experts were allowed to adjust their answers 
in subsequent rounds. After the feedback was received, the 
statements were updated, and first manuscript draft was sent 
for revision of statements and comments.
Experts and all WG members provided commentaries and 
supporting literature for each statement. Finally, all members 
approved the final version of the released statements and 
commentaries.
4. SUMMARY OF RECOMMENDATIONS
4.1. Which patients with CDI should be considered for 
FMT? 
4.1.1. Indication for FMT
4.1.1.1. Recurrent CDI. We recommend that FMT should 
be considered for patients with rCDI who have had at least 
two recurrences, or those who have had one recurrence and 
have risk factors for further episodes, including severe CDI 
(GRADE of evidence: high; strength of recommendation: 
strong).
4.1.1.2. Refractory CDI. We recommend that FMT could 
be considered in cases of refractory CDI (GRADE of evidence: 
low; strength of recommendation: strong).
4.1.1.3. FMT as initial therapy for CDI. We recommend 
that FMT should not be administered as an initial treatment for 
CDI (GRADE of evidence: low; strength of recommendation: 
strong).
4.1.1.4. Apart from CDI, there is insufficient evidence to 
routinely recommend FMT for any other GI or non-GI disease 
(GRADE of evidence: moderate; strength of recommendation: 
strong).
4.1.2. Place of FMT within therapeutic approach for CDI
i. We recommend consideration of treatment with 
extended/pulsed vancomycin and/or fidaxomicin before 
considering FMT as treatment for recurrent CDI in patients 
with severe or complicated CDI. (GRADE of evidence: low; 
strength of recommendation: strong).
ii. FMT could be considered in this setting when medication 
associated with a reduced risk of recurrence (e.g., fidaxomicin 
and bezlotoxumab) are not available. (GRADE of evidence: 
low; strength of recommendation: strong).
4.1.3. Immunocompromised patient
Indication for FMT in immunocompromised patients 
should be considered on a case-by-case basis and only after 
extensive donor screening. Although FMT seems safe, 
we recommend initial consideration of alternative CDI 
management for patients on major immunosuppressive 
agents including high-dose corticosteroids, calcineurin 
inhibitors, mammalian target of rapamycin (mTOR) inhibitors, 
lymphocyte-depleting biological agents, anti-tumor necrosis 
factor agents, and other chemotherapeutic antineoplastic 
agents in the last 12 weeks, uncontrolled HIV (CD4 count < 
240 cells/mm3 ), recent bone marrow transplant (within past 6 
weeks) before offering FMT. (GRADE of evidence: moderate; 
strength of recommendation: weak)
4.1.4. Contraindications
Contraindications are represented by pregnancy, diagnosed 
with toxic megacolon / have anatomic abnormalities that could 
impact delivery method, risk for aspiration with naso-gastric 
(NG) tube, food allergy with previous anaphylaxis (GRADE of 
evidence: low; strength of recommendation: strong).
4.2. Post-FMT follow-up, outcomes and adverse events
4.2.1. Definition of cure/remission
We recommend that a decision regarding cure/remission 
for CDI should be recorded during follow-up. Clinical 
cure should be defined within 8 weeks, in the absence of 
diarrhea. Initial response to FMT should be defined on a 
case-by-case basis. (GRADE of evidence: very low; strength 
of recommendation: moderate)
4.2.2. Definition of treatment failure post-FMT for CDI
We recommend that treatment failure/recurrence should 
be defined on a case-by-case basis. Routine testing for CD 
toxin after FMT is not recommended, but it is appropriate to 
consider in the case of persistent CDI symptoms/suspected 
relapse. Recurrence of CDI should be defined as re-occurrence 
of CDI at more than 2 weeks and before 8 weeks after the onset 
of the initial CDI episode. (GRADE of evidence: low; strength 
of recommendation: strong).
4.2.3. PostFMT immediate management
Patients should be monitored for at least one night 
hospital stay, to document: clinical improvement, stool 
frequency reduction (<3 stools in 24 hours), improvement of 
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stool consistency (< 5 on the Bristol stool chart), absence of 
fever, improvement in vital signs - hypotension, tachycardia 
and/or signs of shock, improvement of other parameters of 
disease severity, laboratory - fall in white cell count and other 
inflammatory markers such as C-reactive protein (GRADE of 
evidence: very low: strength of recommendation: weak.
4.2.4. Management of FMT failure
Initial management of FMT failure could be by a further 
FMT infusion or anti-microbial therapies. The management 
of second FMT infusion failure should be established on a 
case-by-case basis. (GRADE of evidence: low; strength of 
recommendation: strong).
4.2.5. General approach to follow-up post-FMT
i. We recommend that patients should be warned about 
the short-term adverse events, in particular the possibility of 
self-limiting GI symptoms. They should be advised that serious 
adverse events are rare (GRADE of evidence: very low; strength 
of recommendation: strong).
ii. We recommend that all FMT recipients should routinely 
receive follow-up. Clinicians should follow-up FMT recipients 
for long enough to fully establish efficacy/adverse events, and 
for at least 8 weeks in total (GRADE of evidence: low; strength 
of recommendation: strong).
iii. At discharge, patients should be advised to be alert to 
symptoms of recurrent CDI in the first 4 weeks after FMT, 
even if the clinical response was obtained. We recommend 
that patient monitoring after initial favorable evolution after 
FMT should include a telephone call at 1 week after FMT - 
counseling patients to be alert to symptoms and assessing 
primary non-response; telephone call or clinic assessment at 
week 4 to evaluate the patient for a secondary non-response; 
clinical assessment at 8 weeks; telephone call at 12, 24 weeks 
(GRADE of evidence: low; strength of recommendation: weak).
4.3. What recipient factors influence the outcome of FMT 
when treating people with CDI?
4.3.1. Special patient categories
i. We suggest that FMT should be offered with caution to 
several patients’ categories, including CDI and decompensated 
chronic liver disease, solid organ transplant (SOT), intensive 
care unit (ICU) patients (GRADE of evidence: very low; 
strength of recommendation: weak).
ii. We suggest that FMT could be offered with caution to 
patients with CDI and decompensated chronic liver disease, 
after case-to-case judgment and risk stratification, including 
CHILD and Model for End-Stage Liver Disease (MELD) scores, 
albumin level. (GRADE of evidence: very low; strength of 
recommendation: moderate.
iii. FMT can be considered in solid organ transplantation 
recipients; prior use of other available therapies, including 
tapered Vancomycin regimen or Fidaxomycin is recommended 
in this setting. (GRADE of evidence: low; strength of 
recommendation: low)
iv. FMT appears to be effective in selected patients, 
who develop severe and/or recurrent CDI and require ICU, 
but best directed by involving all stakeholders relevant to 
patient’s care. The multidisciplinary team should preferably 
include a ICU therapist, an infectious disease specialist, a 
gastroenterologist and surgeon, and consider the route, timing 
of FMT and potential alternative options. In the ICU setting, 
NG tubes already in place might represent the preferable 
route of administration. (GRADE of evidence: low; strength 
of recommendation: strong)
4.3.2. Other comorbidities and FMT
We recommend that FMT should be considered for 
appropriate patients with recurrent CDI regardless of other 
comorbidities, exerting caution when several characteristics 
for potential increased risk of early FMT failure are present, 
such as: use of non-CDI antibiotics within 8 weeks of FMT, 
history of CDI-related hospitalization, severe or severe-
complicated CDI, pseudomembranous colitis, low serum 
albumin concentration. (GRADE of evidence: low; strength 
of recommendation: strong)
4.4. What donor factors influence the outcome of FMT 
when treating people with CDI?
4.4.1. General approach to donor selection
Where possible, FMT is best sourced from a centralized 
stool bank, from a healthy unrelated donor (GRADE of 
evidence: low; strength of recommendation: weak).
4.4.2. Age and body mass index restrictions for potential 
donors
We suggest that people should only be considered as 
potential FMT donors if they are ≥18 and ≤ 60-years-old and 
have a body mass index (BMI) of ≥18 and ≤25 kg/m2 (GRADE 
of evidence: low; strength of recommendation: weak).
4.4.3. General approach to the donor screening 
assessment
i. It is mandatory to screen potential donors by questionnaire 
and personal interview, to establish risk factors for transmissible 
diseases and factors influencing the gut microbiota (GRADE of 
evidence: low; strength of recommendation: strong).
ii. Biochemical evaluation for the screening of the donor 
is compulsory and should include the following: pathogen 
screening (Hepatitis A IgM, Hepatitis B (HBsAg and HBcAb), 
Hepatitis C antibody, Hepatitis E total antibodies*, HIV-1 
and HIV-2 antibodies, HTLV-1 and HTLV-2 antibodies*, 
Treponema pallidum antibodies (TPHA, VDRL), Epstein–
Barr virus and IgG and IgM, Cytomegalovirus IgG and IgM), 
general metabolic screening (Full blood count, Creatinine 
and electrolytes, Liver enzymes (including albumin, bilirubin, 
ALAT, ASAT, GGT, ALP), C reactive protein) fecal sample 
testing (CD PCR, Campylobacter PCR, Salmonella, and 
Shigella by standard stool culture, Shiga toxin-producing 
Escherichia coli by PCR, Multi-drug resistant bacteria: CPE, 
ESBL, VRE, MRSA, Stool ova, cysts and parasite analysis, 
including for Microsporidia; Acid fast stain for Cyclospora 
and Isospora, fecal antigen for Cryptosporidium and Giardia, 
Helicobacter pylori fecal antigen, Norovirus, rotavirus 
Antigen*), PCR SARS CoV2 nasopharyngeal swabs at 48h 
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interval and stool PCR (*- will require evaluation only when 
FMT will be addressed to immunosuppressed recipients).
4.4.4. Repeat donor checks, and donation pathway
We recommend that a repeat health questionnaire should be 
assessed at the time of each stool donation. To ensure ongoing 
suitability for inclusion as a donor, laboratory screening should 
also be repeated regularly at 3 months (GRADE of evidence: 
low; strength of recommendation: weak).
4.5. What factors related to the preparation and 
administration of the transplant influence the outcome of 
FMT when treating people with CDI?
4.5.1. General principles of FMT preparation
i. We recommend that stool collection should follow a 
standard protocol and that donor stool should be processed 
within 6 hours of defecation (GRADE of evidence: low; 
strength of recommendation: strong).
ii. We recommend that sterile 0.9% saline should be 
considered as an appropriate diluent for FMT production, 
and cryoprotectant such as 10-15% glycerol or maltodextrin-
trehalose cocktail recipes in the ratios of 3:1/ should be added 
for frozen FMT, stored in a -80 °C standard freezer, and then 
later thawed at room temperature). (GRADE of evidence: 
moderate: strength of recommendation: strong)
iii. We recommend using at least 50 g of stool in each 
FMT preparation (GRADE of evidence: moderate: strength 
of recommendation: strong).
iv. We suggest that homogenization and filtration of FMT 
should be undertaken in a closed disposable system (GRADE 
of evidence: low; strength of recommendation: weak).
4.5.2. Fresh versus frozen FMT
We recommend that only the use of banked frozen FMT 
material should be considered. The use of fresh preparations 
should be avoided due to safety concerns. (GRADE of evidence: 
high; strength of recommendation: strong). 
4.5.3. Use of frozen FMT
i. We recommend that FMT material stored frozen at 
−80°C should be regarded as having a maximum shelf life of 12 
months. Refreezing once defrosted is not permitted. (GRADE 
of evidence: low; strength of recommendation: strong).
ii. We suggest consideration of thawing frozen FMT at an 
ambient temperature and using within 6 hours of thawing 
(GRADE of evidence: low; strength of recommendation: weak).
iii.. We suggest not thawing FMT in warm water baths, due 
to the risks of cross contamination with Pseudomonas (and 
other contaminants) and reduced bacterial viability (GRADE 
of evidence: very low; strength of recommendation: weak).
4.5.4. Use of specific medications in the period around 
FMT administration
4.5.4.1. Diet and bowel lavage
i. We recommended a clear liquid diet one day prior 
FMT and bowel lavage to be administered prior to (the 
evening before) FMT via the lower GI route in the absence of 
contraindications; polyethylene glycol preparation is preferred. 
(GRADE of evidence: low; strength of recommendation: 
strong)
ii. Bowel lavage could also be considered prior to FMT via 
the upper GI route in the absence of contraindications (for 
patients with renal impairment adjustment of PEG quantity, 
bowel cleansing should be avoided in patients with severe CD 
colitis and in patients with IBD and CDI, where low-volume 
PEG preparations are preferred. (GRADE of evidence: low; 
strength of recommendation: low).
4.5.4.2. We recommend that proton pump inhibitors (PPIs) 
use should be avoided periprocedurally, considering conflicting 
results on PPIs’ effect in this setting. (GRADE of evidence: 
moderate; strength of recommendation: low)
4.5.4.3. We suggest the use of a single dose loperamide 
(4 mg) on the morning of the procedure, preferably at least 2 
hours before procedure, when FMT is delivered via lower GI 
and in the absence of severe colitis. (GRADE of evidence: low; 
strength of recommendation: weak).
4.5.4.4. Additional antibiotics pre-FMT. We recommend 
the administration of further antimicrobial treatment for CDI 
for at least 72 hours prior to FMT; the preferred antibiotics 
should be either vancomycin or fidaxomycin. (GRADE of 
evidence: low; strength of recommendation: strong).
4.5.4.5. Washout period between antibiotic use and FMT
i. To minimise any deleterious effect of antimicrobials 
on the FMT material, we recommend that there should be a 
minimum washout period of 24 hours between the last dose 
of antibiotic and treatment with FMT (GRADE of evidence: 
low; strength of recommendation: strong).
ii. We suggest considering consultation with infectious 
disease specialists or medical microbiologists for advice 
whenever FMT recipients also have an indication for long term 
antibiotics or have an indication for non-CDI antibiotics within 
8 weeks of FMT (GRADE of evidence: very low; strength of 
recommendation: weak).
4.5.5. Route of FMT delivery
i. We recommend that colonoscopic administration of 
FMT as a first choice route for the treatment for recurrent or 
refractory CDI should be used where appropriate/applicable. 
Other preferred options include duodenal delivery via 
endoscopy; enema; only when these options are not applicable, 
a nasogastric tube can be used. (GRADE of evidence: high; 
strength of recommendation: low).
ii. Where colonoscopic administration is used, we suggest 
considering preferential delivery to the caecum or terminal 
ileum, as this appears to give the highest efficacy rate (GRADE 
of evidence: low; strength of recommendation: weak).
iii. Delivering FMT via an ileostomy as treatment of CDI 
appears to be safe and effective in the treatment of rCDI. 
(GRADE of evidence: low; strength of recommendation: 
strong)
4.5.6. Number of infusions
At least 2 infusions should be considered in patients with 
rCDI showing signs of non-response (persistent diarrhea at 48h 
from first infusion) (GRADE of evidence: moderate; strength 
of recommendation: strong).
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4.5.7. We recommend that best practice for prevention 
of further transmission of CDI should be applied throughout 
when administering FMT to patients with CDI (nursing with 
enteric precautions, sporicidal treatment of endoscope, etc) 
(GRADE of evidence: high; strength of recommendation: 
strong).
4.6. Basic requirements for implementing a FMT service 
4.6.1. General considerations 
In Romania, FMT will be performed under the regulations 
of the Ministry of Health, only in credentialed university 
centers, where infrastructure is available. (GRADE of evidence: 
low; strength of recommendation: strong).
4.6.2. Minimum infrastructure requirements should be 
fulfilled in order to achieve microbiological safety (outpatient 
room, sample FMT preparation and storage rooms with 
separate ventilation system and controlled environment- 
temperature, humidity). Minimum equipment include category 
2 hood, clean but not sterile, equipped with scale, stomacher, 
separate ventilation system.  (GRADE of evidence: moderate; 
strength of recommendation: strong)
4.6.3. FMT manufacturing and production quality 
control
i. We recommend ensuring the traceability of supply 
(GRADE of evidence: very low; strength of recommendation: 
strong).
ii.  We recommend monitoring, notification and 
investigation of all adverse events and reactions related to FMT 
(GRADE of evidence: very low; strength of recommendation: 
strong).
iii. We recommend ensuring the traceability of supply, 
using a quality system that relies on the principles of good 
clinical practice. (Quality of evidence: law governed; grade of 
recommendation: strong
iv. We recommend the creation of at least a local database 
(preferably a national database) including FMT recipients’ data 
with careful monitoring of response to FMT and report adverse 
events, for a minimum 8 week follow-up, and a donor registry 
minimally including the date when donor screening process 
had begun and was completed, the date of the last completed 
screening process. (GRADE of evidence: low; strength of 
recommendation: strong).
4.6.4. Donor screening governance
We recommend each center to establish a local clinical 
governance board, including at least a gastroenterologist, 
infectious disease specialist, microbiologist and epidemiologist.
(GRADE of evidence: low; strength of recommendation: 
strong)
4.6.5. Credentialing and recredentialing of FMT centers
i. Credentialing should include the evaluation of the 
performance indicators of the activity of the center.
ii. Interval for recredentialing should be 3 years
iii. The credentialing and recredentialing process must 
include: National Insurance House, the Ministry of Public 
Health, the Public Health Regulatory Council (Directia 
de Sănătate Publică județeană) and professional Societies: 
Romanian Society of Gastroenterology, Romanian Society of 
Microbiology.
4.6.6. Multidisciplinary teams
We recommend that a multidisciplinary team should be 
formed to deliver FMT services (GRADE of evidence: very 
low; strength of recommendation: strong).
5. RATIONALE FOR 
RECOMMENDATIONS
5.1. Which patients with CDI should be considered for 
FMT? 
There is significant evidence for the efficacy and safety of 
FMT for the treatment of recurrent CDI [25-30].  In defining 
recurrent CDI, there have been various definitions, mainly 
relying on a minimum threshold of the return of clinical 
symptoms (e.g., at least three unformed bowel movements 
within 24 hours, for at least 2 consecutive days), with the latest 
ECDC definition including the reappearance of symptoms 
in the following 2 to 8 weeks after previous successful CDI 
treatment [1, 28, 31]. Moreover, the current data are relatively 
heterogeneous concerning the methodology for performing 
FMT and also the definition used for the resolution of CDI [8].
The choice of FMT in this setting should balance the risks 
and benefits and should guide a joint decision of either FMT 
or (tapered) antibiotics with or without additional treatment 
with e.g. monoclonal antibody or nonabsorbable antibiotics. 
One randomized controlled trial (RCT) performed by Hvas CL 
et al. [30] showed that FMT after vancomycin administration 
was superior to fidaxomicin and vancomycin monotherapies 
for rCDI for combined clinical and microbiological resolution 
and clinical resolution alone. 
For refractory CDI, even though exclusion of other causes 
is required (for example ulcerative colitis, microscopic colitis), 
FMT as rescue treatment appears encouraging, although few 
studies have addressed  the effects of FMT in patients with 
refractory or severe CDI [32-37]. Furthermore, FMT appeared 
to decrease mortality in patients with severe CDI refractory to 
antibiotic therapy [34-36, 38], and could also be considered 
as a therapeutic option for this condition, with decision taken 
on a case-by-case basis.
Considering some particular patient-related aspects of 
CDI infection in potential FMT recipients in Romania, such 
as increased age [4] and also the prevalence of ribotype 027 
[3], the working group discussed the opportunity for the use of 
FMT among patients with one CDI recurrence and risk factors 
for other recurrences. We considered the risk factors identified 
in literature, namely antibiotics use for non-C. difficile after 
CDI diagnosis, long term gastric acid suppression, severe 
underlying disease and/or renal insufficiency/ severe illness 
by Horn index, previous severe CDI, prolonged hospital stays, 
severe underlying disease and/or renal insufficiency, a history 
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of previous CDI, previous CDI severity, prolonged hospital stay 
hypervirulent strain, NAP1/BI/027 [39, 40]. Although there is 
limited evidence in RCTs, experts agreed that FMT could be 
indicated after one recurrence for those with features of severe 
disease or risk factors for recurrence. 
Nowadays there is increasing interest in exploring wider 
opportunities for FMT in the course of various disease although 
studies confirming the efficacy of FMT in this setting are limited 
or contradicting. Among areas with promising results is the use 
of FMT for ulcerative colitis (UC), with significant difference 
in achieving remission reported in two RCTs including UC 
patients undergoing colonoscopically administered FMT, with 
prior bowel lavage [41, 42]. However, another RCT including 
UC patients who were administered FMT via duodenal 
tube did not identify significant differences in achieving 
remission [43]. One RCT including Crohn’s disease patients 
with colonic or ileocolonic disease, who were administered 
FMT colonoscopically, with prior bowel lavage identified no 
difference in sustained engraftment between allogeneic FMT 
and sham, but a decrease in Disease Endoscopic Index of 
Severity at 6 weeks was obtained in the group receiving FMT 
[44]. Regarding the use of FMT for irritable bowel syndrome, 
among the 7 RCTs available to this moment, all with various 
study protocols and routes of administration, conflicting results 
have been reported [45-50].
Extra-digestive indications which are studied for FMT 
include hepatic encephalopathy, with an RCT showing 
significant reduction in new hepatic encephalopathy episodes 
among cirrhotic patients receiving FMT [51] and potential 
for eradication of multidrug resistant organisms, with a 
randomized open label study which indicating a lightly 
decreased ESBL-E/CPE carriage among patients who received 
FMT [52]. Taking into account all the above-mentioned 
evidence, FMT for other indications than CDI should 
preferably be currently limited only to the research setting or, 
in the absence of alternative therapeutic option.
5.1.2. Place of FMT within therapeutic approach for CDI
At least two licensed agents (fidaxomicin and bezlotoxumab), 
are available having demonstrated they significantly reduce the 
risk of CDI recurrence compared with vancomycin. [53, 54]. 
These potential medications should also be considered for 
recurrent CDI. 
However, considering evidence suggesting the superiority 
of FMT over the use of fidaxomicin in recurrent FMT (30) 
and also the financial limitations of using fidaxomicin or 
bezlotoxumab in Romania, the local members of the working 
group strongly encouraged using FMT for rCDI after failure 
of extended/pulsed vancomycin. Moreover, since it has been 
suggested that additional antibiotic treatment with vancomycin 
after first FMT infusion, followed by a second FMT, could 
contribute to improving outcomes in patients with severe 
CDI [55, 56]. However, in most case reports, the patients 
responded to a single FMT without additional antibiotic 
treatment, suggesting that a combined treatment is not 
necessary in all patients. More research is needed to determine 
the additional value of sequential FMTs followed by antibiotic 
treatment, especially in relation to the presence or absence of 
pseudomembranous colitis. 
5.1.3. Immunocompromised patient
Although there is increasing evidence that FMT in 
immunocompromised patients appears safe [57], there 
are still reports of severe adverse events, including death, 
following transfer of multi-drug resistant organism calls 
for particular caution in this patient group [58].  Food and 
Drug Administration (FDA) issued a safety alert On June 
13, 2019, regarding the risk of serious adverse reactions due 
to transmission of multi-drug resistant organisms (MDRO) 
through FMT to two immunocompromised patients, among 
which one resulted in death [59]. In this particular case, the 
donor had not been screened for MDRO. Consequently, the 
inclusion of MDRO screening in all active and future FMT-
based study protocols must be performed and the precise 
status of immunocompromised patients will be determined by 
the members of the multidisciplinary team involved in FMT.
Since only limited data is currently available on the 
risks of FMT in patients at specific different levels of 
immunosuppression, the local members of the working group 
expressed the need for careful consideration when using 
FMT in immunocompromised patients and highly encourage 
judicious application of FMT in this patient category, along 
with thorough surveillance for and documentation of adverse 
events and long-term follow-up in immunocompromised 
patients.
5.1.3. Contraindications for FMT
There are no known absolute contraindications for FMT 
based on the current clinical evidence [60]. However, the 
procedure has not been adequately studied in pregnancy and 
should be delayed until the patient is postpartum [61].
Colonoscopy route of delivery is more effective than enema, 
although, when toxic megacolon is diagnosed or the patient 
has anatomic abnormalities the colonoscopy is contraindicated 
and the nasoduodenal route should be preferred [62]. 
Although no cases of allergy, anaphylaxis or anaphylactic 
shocks have been reported in the literature, the food allergies 
should be evaluated in recipients before FMT. If the patient 
reports a severe food allergy, either the patient should be 
evaluated by an allergist to confirm the allergy or, if the allergy 
is confirmed, the stool source should from a donor who has 
abstained from the allergenic agent for a period of 7 days [12]. 
5.2. Post-FMT follow-up, outcomes and adverse events
5.2.1. Definition of cure/remission
There are significant reports that symptoms of CDI resolve 
relatively fast after a successful FMT, although the timing for 
defining a favorable course varied between few hours in some 
studies [63] to an average of 4–5 days in others [64].There is no 
uniformly agreed definition for treatment success post-FMT 
for CDI, but most evidence lays on clinical criteria, assessing 
treatment response as present when stool frequency decreases 
to less than 3 per 24 hours (or returning to the prior defecation 
frequency) over a period of at least 72 hours, criteria which 
can also be combined with improvement of disease severity 
parameters (clinical, biological).
Moreover, since ECDC definition of recurrence is between 
2 weeks following treatment and before 8 (1), the absence of 
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symptoms within 8 weeks from the FMT is also to be considered 
when evaluating cure/remission [13]. The use of FMT as 
treatment for recurrent or refractory CDI infection and other 
potential indications: joint British Society of Gastroenterology 
and Healthcare Infection Society guidelines [13, 65]. The 
working group agreed that the definition should be made on a 
case-by-case basis but should include an assessment for cure/
remission of CDI within 8weeks.
5.2.2. Definition of treatment failure post-FMT for CDI
FMT failure can be defined only based on clinical criteria, 
as persistence of diarrhea after the procedure or recurrence 
of diarrhea after initial improvement within 8 weeks after the 
procedure [66] or using both clinical and laboratory testing 
for CDI, as diarrheal symptoms (≥3 loose stools within a 24-
hour period) and a positive CD stool test. The WG agreed that 
definition on a case-by-case basis is adequate in this setting 
and that decision regarding cure/remission from CDI should 
be recorded during follow-up.  
Considering that up to 80% of failures happen before 
week 4, with the mean failure time at 2 weeks after FMT [66], 
it is important to prior acknowledge potential risk factors 
for failure. These factors include: ongoing antibiotic use, age, 
number of admissions prior to FMT [32],  antimicrobial 
exposure pre-FMT or continuing antibiotic use during 
or directly following FMT [67] and also severe CDI and 
inadequate bowel preparation [68]. However, it must be 
considered that a substantial number of recurrences occur 
after 8 weeks from FMT delivery and the appearance of a new 
CDI episode later than 8 weeks post-FMT should be regarded 
as a late recurrence [69]. 
5.2.3. PostFMT immediate management
There is often a relatively short period of post-procedural 
observation in patients receiving FMT [27, 31]. Since, usually, 
most of the immediate side-effects of post-endoscopic 
administration of FMT are minor and self-limiting [70], 
most FMT centers usually manage patients by the standard 
protocols for an endoscopic procedure [71, 72], without any 
specific adaptations, apart from advising about the possibility 
of self-limiting GI side effects and following the protocol 
of departmental infection control. Consequently, the post-
procedural period of observation is relatively short [21, 
27], allowing patients to leave the administration site after 
the period of observation. However, overnight observation 
protocol was applied for a cohort of elderly patients with 
multiple comorbidities undergoing FMT [73]. 
Depending on the severity of CDI, patients should be 
monitored in order to evaluate initial treatment response, at 
least on clinical grounds, following several parameters such as 
stool frequency reduction (<3 stools in 24 hours), improvement 
of stool consistency (< 5 on the Bristol stool chart), absence of 
fever, improvement in vital signs - hypotension, tachycardia 
and/or signs of shock [12]. Moreover, when baseline 
biochemical parameters have been modified, then at least 
the decrease in white cell count and other inflammatory 
markers such as C-reactive protein, fibrinogen should also 
be monitored.
Although in cases with non-severe CDI there is no need 
for an overnight hospital stay, the local members of the 
working group considered at least one night hospital stay 
would be useful for monitoring. This statement has been 
locally supported, considering that most cases of rCDI in 
Romania are often met in frail patients with comorbidities, 
exhibiting moderate-severe colitis and because access to 
prompt readmission in case of unfavorable evolution may be 
limited in some situations. 
5.2.4. Management of FMT failure
FMT has been successful in controlled trials, but there 
is potential for treatment failure or incomplete resolution of 
patient symptoms. Patient expectations should be calibrated 
appropriately during the discussion. Predictors of treatment 
failure include severe and severe-complicated CDI, inpatient 
status during FMT, and the number of previous CDI–related 
hospitalizations [32] as well as underlying inflammatory bowel 
disease [74].
In a systematic review about FMT use for the treatment 
of CDI, a total of 25 case series and two RCTs were identified 
providing evidence on the efficacy of FMT for recurrent, 
refractory, or even an initial episode of CDI, with most studies 
targeting recurrent CDI [25]. The largest of these studies was 
an unblended RCT which compared FMT to oral vancomycin 
(14 days) or oral vancomycin (14 days) plus gastrointestinal 
lavage [27]. The study was terminated early due to a significant 
difference in recurrence between the FMT group and the 
two control groups. Apparently, 81% of patients in the FMT 
arm had sustained resolution of diarrhea after the first fecal 
transplant compared with 31% of patients in the vancomycin 
arm and 23% of those in the vancomycin plus bowel lavage 
arm. We should keep in mind that most of the study enrollees 
had four episodes of CDI before enrolment, making them 
a different population than other trials [27]. Furthermore, 
repeating FMT in patients who failed the first FMT found to 
improve the response rate to 94% [27, 75]. Another RCT of 39 
adults with recurrent CDI demonstrated comparable efficacy 
of FMT (with median of three recurrences per patient) [25].
A two-week standard course of oral vancomycin or 
repeated instillation of feces collected from new donors might 
be a solution for patients who initially fail to respond to fecal 
instillation [68] and vancomycin taper associated with a lesser 
chance (85% reduction in risk) of a relapse following FMT 
[32]. A second administration of FMT by enema after a first 
failure (elderly patients  possibly attenuated the sphincter tone 
in elderly patients) [76].
5.2.5. General approach to follow-up post-FMT
Most frequently reported short-term adverse events post-
FMT for CDI are mild, and include mainly self-limiting GI 
symptoms. These may include nausea [21, 27, 60, 72], bloating 
[25, 26, 30], belching [27], abdominal cramps/pain [26, 28, 
29, 31], diarrhea [21, 27, 31]. These symptoms typically 
resolve within a few hours to days [21, 27, 72]. Except for the 
short-term minor adverse events, long-term adverse reaction 
(such as postinfectious irritable bowel syndrome) [77] and 
also severe adverse events should be reported and a clear 
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distinction between procedure-related versus unrelated need 
to be made. 
Serious events related to the way of administering FMT 
are rare, but they occur and may be due to complications of 
endoscopy, such as perforation and bleeding or adverse effects 
related to sedation, such as aspiration (one death reported 
after aspiration during sedation for FMT administered via 
colonoscopy [60]; death of two patients from pneumonia 
on aspiration of feces administered to the duodenum via 
enteroscopy or nasoduodenal tube was reported [38, 77]. 
Moreover, deaths after an initial positive response to 
FMT but with subsequent development of ileus and colonic 
perforation and death in individuals with the ribotype 027 
CDI strain who never responded to FMT and died within 
three months [8] were also reported. There has also been 
reported transmission of enteric pathogens via FMT: cases of 
documented norovirus infection 2 days and 12 days after FMT 
[78], a case report of fever and Escherichia coli bacteremia 24 
hours after FMT via colonoscopy in a patient with IBD [58] 
and infections caused by enteropathogenic Escherichia coli 
and Shiga toxin-producing Escherichia coli [79].
All side effects and severe side-effects should be reported 
and registered within the available local database by the 
treating physician, within 48 hours after occurrence, even if 
apparently initially not relatable to FMT, especially considering 
that usually they have been underreported [77, 80].  In case of 
severe adverse events, prompt and effective procedures for the 
disposal of the used FMT material should be applied.
Follow-up of patients undergoing FMT is compulsory, 
but there is significant variability in the way which post-FMT 
follow-up was performed, both in terms of duration and 
modality (outpatient visits, telephone interviews, electronic 
diary or standardized questionnaires) [66, 81, 82].
In the context of COVID-19, patients should be instructed 
to immediately contact the center where FMT was performed 
if symptoms of infection develop or if they are diagnosed 
with COVID-19 within 28 days of the procedure. Moreover, 
follow-up appointments at different time points (between 1 
and 8 weeks) should be conducted as much as possible, via 
internet if possible, or via phone calls, in order to assess signs 
of recurrence and identify potential symptoms of infection, 
excepting the situations where direct assessment is mandatory 
[83].   
After the most recent definition of rCDI from ECDS, 
most studies and current guidelines use a follow-up period 
of at least 8 weeks. Our WG decided that at least 8 weeks of 
follow-up was appropriate post-FMT to completely evaluate 
efficacy and potential adverse events. However, since there is 
some concern about long-term side effects of FMT, including 
weight gain, the development of IBD, cancer, autoimmune 
diseases, allergies, or neurological diseases, a national or at 
least local registries should be developed in order to perform 
long-term follow-up [84].
5.3. What recipient factors influence the outcome of FMT 
when treating people with CDI?
Special patient categories and other comorbidities: several 
patient characteristics such as immunocompromised state, 
decompensated liver cirrhosis, critically ill patients requiring 
intensive care unit (ICU), all of them with their own risks 
of unfavorable outcome. Although evidence has been 
limited for most groups, currently there is increasing data in 
immunocompromised patients, supporting the use of FMT for 
treatment of CD infection in immunocompromised patients, 
with similar rates of serious adverse events to immunocompetent 
patients [85]. FMT in immunocompromised patients appears 
to have comparable efficacy and safety data to those on patients 
with intact immunity, but practitioners should perform FMT 
in solid organ transplantation (SOT) recipients with refractory 
CDI with vigilance for infectious complications [86-88]. 
For SOT patients, there is data from a RCT suggesting 
FMT is safe. The study reported FMT-related adverse events 
in 22.3% of cases, mainly comprising self-limiting conditions 
including nausea, abdominal pain, and FMT-related diarrhea. 
Severe adverse events were registered in 3.2% of cases, with no 
FMT-related bacteremia; however, among cytomegalovirus-
seropositive patients’ reactivation was reported. Repeated 
FMT or additional antibiotics may be needed to optimize 
rates of cure with FMT within this patient category [89] and 
consequently an indication for FMT should me more carefully 
considered in this patient category.
A study including cirrhotic patients, aiming to assess safety, 
tolerability and impact on microbiota and brain function in 
hepatic encephalopathy of capsulated FMT, demonstrated 
that oral FMT capsules appear to be safe, and even improved 
EncephalApp performance [90]. Another study including 
patients with chronic liver disease, among which 9 with 
cirrhosis and 1 recipient of liver transplantation, FMT was well 
tolerated, without infectious complications [91].
For critically ill patients receiving rescue FMT the 
procedure appears to be safe [92]. Moreover, in another study 
FMT provided mortality benefit over standard of care for severe 
and fulminant CDI and should be considered in critically ill 
patients [93]. The route of administration should be decided 
within the multidisciplinary team [94].
5.4. What donor factors influence the outcome of FMT 
when treating people with CDI?
5.4.1. General approach to donor selection
The selection of possible donors is one of the key points 
for FMT safety and efficacy. In principle, donors genetically 
related to FMT recipients showed similarities in their intestinal 
microbiota [94], because donors and recipients living in the 
same house are largely exposed to the same infectious risk 
factors and allergens [95]. However, FMT has also been 
successfully performed with donor feces from unrelated 
healthy volunteers [96]. The success rates of FMT for recurrent 
CDI are comparable for related and unrelated donors (89.5% 
vs. 90.7%) [97]. The advantage of donor feces in terms of 
relationship status for indications other than CDI remains 
uncertain. There is also a theoretical advantage of a common 
genetic background and shared environment, leading to better 
immunological tolerance of the FMT. Nevertheless, additional 
clinical evidence has proven no association between donor 
and FMT outcomes [98, 99], and either related or unrelated 
donors are acceptable in different countries [13, 100]. Unrelated 
FMT volunteer donors may be more beneficial in cases where 
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genetics could influence the disease outcome. Consequently, 
no specific recommendation is made, and the donor can be a 
family member or have no relationship with the recipient. In 
all cases, the same screening tests should be carried out.
5.4.2. Age and body mass index restrictions for potential 
donors
Although there is currently no consensus on age restrictions 
for potential FMT donors, many studies included donors 
between 18 and 60 years old, potentially due to the fact that 
there is a decrease in gut microbiota stability and diversity in 
people who are 60 years and older [101, 102] and also that 
there might be undiagnosed oncologic or cardiovascular 
comorbidity in potential donors over 60 years of age. 
As far as BMI restrictions are concerned, there have been 
case reports of weight gain in a recipient following FMT 
from an overweight donor [103].  On the contrary, a large 
retrospective cohort study highlighted that single FMT did 
not determine weight gain in FMT recipients  [104]. As it is 
currently recommended in the available guidelines, donors 
exciding the normal BMI range of 18-25 should be excluded 
from becoming stool donors, until further prospective studies 
confirm otherwise [12, 13]. 
5.4.3. General approach to the donor screening 
assessment
An extensive screening questionnaire and a strict panel 
of tests for donor screening are recommended prior to FMT 
in order to reduce and prevent the occurrence of adverse 
events. Both the guidelines in the United States and European 
consensus conference suggest to use a donor questionnaire 
to evaluate the exclusion and inclusion criteria. The donors 
should undergo an additional interview on the same day of 
the donation. Standard donor screening protocols should be 
set up to decrease the risks of infection transmission from the 
donor to recipient, and it should include both blood and stool 
examinations within 4 weeks before donation (Supplementary 
Table III). 
The incidence of SARS-CoV-2 infection raised concerns 
about the potential for transmission through feces, and  FDA 
released a safety alert on FMT and donor screening in March 
2020 [105]. The safety alert recommended that a donor stool 
obtained after December 1, 2019 should be tested for SARS-
CoV-2 before being used to treat patients. Subsequently, an 
international expert panel proposed donor screening measures 
including PCR assays of nasopharyngeal swab samples and 
direct testing of donor feces once a test is available, given the 
uncertainties around the risk of transmission via FMT [15, 
83], although there are no data on the clinical outcomes in 
patients who received a donor stool from an infected donor 
with SARS-CoV-2. 
In addition, screening for transmissible diseases or 
factors disturbing the gut microbiota should be conducted 
with a questionnaire and personal interviews [13, 100] and 
comprehensive blood and stool tests are both prerequisites 
[100].
If the donor is considered a qualified candidate, the stool 
donation should be conducted within 4 weeks [12]. An 
interview on the day of the donation should be conducted to 
check for potentially health issues with recently onset [12]. 
The donor’s stool should be processed within 6 h of defecation 
[13]. Besides, the donor is asked to be interviewed again 1-2 
months after the stool donation. If there are any suspicious 
risk factors noted during follow-up, further examinations and 
surveillance are mandatory [13], along with quarantine of the 
sampled stool for 2 months in view of safety regarding SARS-
CoV-2 transmission. If the eligible donor is willing to donate 
stool again, the screening process shall be conducted at least 
every 4 months [13].
5.4.4. Repeat donor checks
Donors repeatedly used for FMT should be retested every 
3 months, and sooner in the case of certain risks for infectious 
diseases (e.g. vacation in countries with a high risk for gastro-
intestinal infections, contact or history of COVID-19).
5.5. What factors related to the preparation and 
administration of the transplant influence the outcome of 
FMT when treating people with CDI?
5.5.1. General principles of FMT preparation
The stools are collected in a disposable container with a 
wide opening and a tight lid, and the sample for FMT must not 
contain urine. Preparation of stool is carried out in a dedicated 
room. It is performed in a biosafety cabinet to avoid the risk of 
cross-contamination and ensure the protection of personnel. 
All preparation steps are performed at room temperature.
Preparation of fecal material from donor is as follows: 
200 mL of diluent (water or NaCl 0.9%) was added to 50 g of 
stool and homogenized into a liquid suspension, placed in the 
bag mixer. Reports have shown that FMT is more effective if 
amount of feces used is more than 50 g increases, in comparison 
to the use of feces more than 50 g) [106] (Supplementary file, 
Table IV). Next, the mixture was allowed to settle for 5 min and 
then filtered first through the gauze. Filtrate obtained in the 
syringes can be frozen and thawed without loss of efficiency, 
which allows long-term storage of those materials. Also, the 
fecal materials obtained from the donor can be frozen at −80°C 
with the addition of glycerine [107]. Glycerol is added to the 
liquid preparation (final concentration, 10%) for storage, to 
increase the viability of the microbiota  [71].
It is essential to ensure rigorous traceability of the FMT. 
For this purpose, biological samples from the donor should be 
stored and a batch file must be created and archived. For each 
FMT, two samples from the donor are stored at -80 °C. Stool 
collection: 1–2 g of stool collected at the time of the donation, in 
a polypropylene tube Sample collection: 1–5 mL of preparation 
administered to the recipient in a polypropylene tube
5.5.2. Fresh versus frozen FMT
Recent severe adverse events due to inadvertent transfer 
of pathogens during FMT in the US and the potential for 
transmission of SARS-CoV-2 during FMT make it imperative 
that all fecal samples used for FMT are thoroughly screened. 
This requires a period of quarantine between stool processing 
and use of FMT which is not possible using fresh stool. We 
therefore do not recommend the use of fresh stool samples for 
FMT. In summary, the use of frozen product is logistically less 
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cumbersome, and it is also advisable from the point of view of 
patient safety, especially in the current context of COVID-19 
pandemic. 
5.5.3 Frozen FMT
The simplest way to process the donor’s microbiome is 
to liquefy the donor stool in normal saline and then filter it 
to eliminate the cellular component. This suspension will be 
frozen at –20 to –80°C for later use. The main advantage of 
the frozen product is its ready availability whenever needed, 
excluding a time-consuming donor screen and preparing the 
stool sample for administration on short notice. In this case 
the composition of the microbiota and their viability will then 
remain unchanged, even after six months of storage at –20 to 
–80°C [25, 26]. Successful treatment of rCDI with samples 
that have been stored for 9 to 12 months has been reported. 
Multiple retrospective analyses and randomized trials [21, 71, 
108, 109] have compared the efficacy of fresh and frozen FMT 
without revealing any significant difference.
5.5.4. Use of specific medications in the period around 
FMT administration
5.5.4.1. Diet and bowel lavage 
Bowel lavage has been used prior to FMT in order 
to remove residual antibiotics which could impair the 
engraftment of transplanted microorganisms, and also 
to remove residual CD spores and vegetative cells [110-
112]. It has already been stated that the efficacy of FMT 
may depend upon the technique used to cleanse the colon 
before administration of the FMT [113] Bowel lavage with 
polyethylene glycol preparations is usually recommended 
with very good results, especially before FMT administration 
via colonoscopy [31], but it is sometimes also prescribed with 
good results before FMT administration via upper GI route 
[27, 38, 114]. It is not known if bowel lavage is required before 
donor feces infusion but given the excellent results of FMT 
after bowel lavage using polyethylene glycol preparations, it 
is generally prescribed. However, FMT can be considered 
without bowel lavage as well, as it has been done in several 
studies, apparently without a reduction in efficacy [21]. 
Positive results have also been reported for subjects who 
stopped antibiotics or probiotics 48 hours before the procedure, 
followed a clear liquid diet a day before FMT, and received 10 
oz. of magnesium citrate or Golyetly for subjects with kidney 
function impairment the night before the procedure [115]. 
Since IBD patients represent a special patient category when 
discussing bowel preparation, it is important to consider low-
volume preparations for these patients, since they are well 
tolerated, without more frequent side effects in patients with 
relatively inactive IBD than the general population, as it has 
been emphasized by a meta-analysis focusing on cleansing 
preparations in patients with IBD [116]. It is still unclear 
whether this could be safely administered to patients with more 
active IBD and CDI, or whether tap water enema could be an 
alternative. For the moment, the working group concluded that 
caution when recommending bowel lavage in IBD patients with 
CDI or CD colitis should be taken and that either no bowel 
prep or low-volume PEG solution should be preferred.
5.5.4.2. PPI use
A potential benefit of PPI use prior to upper GI FMT could 
reside in minimizing the effect of gastric acidity on altering 
engraftment of transplanted microorganisms [16, 67, 117]. 
PPIs might change microbiota [118] with moderate alterations 
occurring to both upper and distal gut microbiota [119]. No 
clinically significant benefit from routine use of PPIs in FMT 
protocols were identified [120, 121].  Considering all these 
aspects, the WG suggested that PPI use should be avoided 
peri-procedurally, considering conflicting results on PPIs’ 
effect in this setting, until further steps are taken to optimize 
protocols for safety and efficacy. 
5.5.4.3. Loperamide use
A single dose/short course of loperamide was used for FMT 
recipients (predominantly for lower GI administration) with 
the purpose of extending exposure of the FMT to the mucosa, 
and to enhancing retention of the FMT within the GI tract [33, 
67, 72, 81, 109, 121].  
However, no in-depth analysis regarding these factors 
has been performed. Considering the pharmacokinetics 
of loperamide and the potential benefit in improving FMT 
retention, the WG agreed that a single-dose administered at 
least 2 hours before procedure, when FMT is delivered via lower 
GI and in the absence of severe colitis could be recommended, 
until further evidence is available.
5.5.4.4. Additional antibiotics pre-FMT and washout 
period between antibiotic use and FMT
Many studies on  FMT included patients who had 
previously received conventional antimicrobial therapy, 
mainly with vancomycin or metronidazole [26, 28, 31]. One 
difference in various protocols of FMT for rCDI resides in 
the use of antibiotics, both the type of antibiotic and length 
of administration, ranging from 1 to 4 days prior to FMT 
[122, 123]. Since it has been hypothesized that antibiotic 
prior to FMT might lead to a more effective engraftment of 
the donor microbiota to the recipient, generating a higher 
similarity between donor and recipient microbiota profiles 
after FMT and there are proof from preclinical studies that 
antibiotic treatment prior to FMT did not improve the overall 
engraftment of donor microbiota [124]. More direct evidence 
is required in order to generate specific protocol in this regard. 
Furthermore, since antibiotic exposure prior and 
immediately after FMT has been identified as a predictor of 
FMT failure [67] a wash-out period of antibiotics should be 
considered prior to FMT infusion [104]. 
5.5.5. Route of FMT delivery
Administration of donor faeces can be performed via 
a nasogastric or nasoenteric tube, gastroduodenoscopy, 
colonoscopy, flexible sigmoidoscopy, enema or capsules. 
Although there is recent evidence that administering FMT 
using a nasogastric tube as route of administration is safe 
and effective [125] taking into account a recent meta-analysis 
evaluating the efficacy outcome of FMT depending on the 
route of administration suggested that colonoscopy is the most 
effective route, the WG supported using a colonoscopy as a first 
choice administration route whenever applicable, especially 
considering that FMT in Romania would be administered in 
credentialed tertiary centers, where colonoscopy is readily 
available. The same meta-analysis calculated cure rates were 
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78% identified and considering single infusion and 98% 
after overall infusions and identified that multiple infusions 
increased efficacy rates for each evaluated route of delivery 
(duodenal delivery: 73% with single infusion vs. 81% with 
multiple infusions; capsule: 80% vs. 92%; colonoscopy: 78% 
vs. 98% and enema: 56% vs 92%) [106]. However, it should 
be noted that the reported success rate when administering 
FMT by colonoscopy seems also dependent on delivering the 
transplant to the cecum. This may not be accessible in patients 
with severe colitis, in whom colonoscopy must be performed 
with caution, in order to minimize the risk of perforation, 
which makes consideration for upper GI route in these cases. 
Although there is scarce data regarding FMT for treatment 
of rCDI in patients with stomas, the available reports on FMT 
delivered by upper endoscopy via an ileostomy was successful 
in treating severe complicated rCDI, without noticeable adverse 
events [126]. 
It is recommended that all patients, healthcare providers 
and staff wear surgical facemasks at all times. FMT procedures 
involving mucous membranes including nasoenteric tube 
insertion, upper endoscopy or colonoscopy require N95 masks 
and face shields to be worn by personnel who perform the 
procedure and any members of the healthcare team present. 
5.5.6. Number of infusions
At least 2 infusions should be considered in patients with 
rCDI showing signs of non-response persistent diarrhea at 
48h from first infusion. Despite having identified independent 
factors that may predict treatment failure after single 
infusion, as poor bowel preparation, endoscopic finding of 
pseudomembranes [68], and severe infection [32], there is a 
lack of validated criteria to guide the decision regarding the 
timing and number of infusions [127]. A recent meta-analysis 
confirmed that multiple stool infusions decreased with 76% the 
risk of rCDI [128]. Multiple infusion feces could significantly 
improve the effect of treatment. Ianiro et al. [36] found that 
a FMT protocol consisting of multiple fecal infusions and 
concomitant vancomycin was significantly more effective 
than a single FMT followed by vancomycin in curing severe 
CDI patients. 
6. BASIC REQUIREMENTS FOR 
IMPLEMENTING A FMT SERVICE
There are different regulations for FMT among countries, 
and global regulation is lacking [12, 129]. In the United 
Kingdom, the Medicines and Healthcare Products Regulatory 
Agency guides FMT practices, and an institute can conduct 
FMT legally after gaining permission from the agency [13]. 
The United States FDA initially considered FMT a drug, but the 
“enforcement discretion” regarding investigational new drug 
applications provided a possible means for FMT in patients 
with unresponsive or rCDI [130].
Authorities must regulate FMT to safeguard patients and 
donors, promote further research into safety and efficacy, and 
avoid abuse of the treatment. In 2012, the FDA classified human 
feces as a drug. However, The European Medicine Agency has 
not defined its position, leaving each country free to assign 
a qualification. In France, FMT is considered a drug by the 
National Agency for Medicine and Health Product Safety, 
placing the fecal material under the jurisdiction of the hospital 
pharmacy [131]. Thus, its production should be carried out 
under the responsibility of pharmacists and storage within 
the pharmacy. Other European countries such as Austria or 
Finland see FMT as a therapeutic intervention that should not 
be considered a pharmaceutical drug and did not consider 
relevant to establish specific regulations. In those countries, 
doctors may perform FMT based on their own judgment 
without any approval from the drug authority [132].
Considering the potential side effects of FMT, this 
procedure should be authorized by the Ministry of Health and 
the credentialing and recredentialing process must involve 
the National Insurance House, the Ministry of Public Health, 
the Public Health Regulatory Council and the professional 
Societies: Romanian Society of Gastroenterology, Romanian 
Society of Microbiology. 
In Romania, FMT will be performed under the regulation 
of the Ministry of Health, only in credentialed university 
centers, where infrastructure is available. We recommend that a 
multidisciplinary team should be responsible to complete FMT 
services. All adverse events and reactions related to FMT will be 
monitored and notified. Minimum infrastructure requirements 
should be fulfilled in order to achieve microbiological safety 
(outpatient room, sample FMT preparation and storage rooms 
with separate ventilation system and controlled environment- 
temperature, humidity). Minimum equipment includes: -80°C 
freezer, category 2 hood, clean but not sterile, equipped with scale, 
stomacher, and separate ventilation system. During FMT, we have 
to ensure the traceability of supply, monitoring, notification and 
investigation of all adverse events and reactions related to FMT. 
We recommend the creation of at least a local database (preferably 
a national database) including FMT recipients’ data with careful 
monitoring of response to FMT and report adverse events, for 
a minimum 8-week follow-up, and a donor registry minimally 
including the date when donor screening process had begun and 
was completed and finally the date of the last completed screening 
process. Each center should establish a local clinical governance 
board, including at least a gastroenterologist, infectious disease 
specialist, microbiologist and epidemiologist.
Credentialing should include the evaluation of the 
performance indicators of the activity of the centre and the 
interval for recredentialing should be 3 years. The credentialing 
and recredentialing process must include the following 
competent institutions: The National Insurance House, the 
Ministry of Public Health, the Public Health Regulatory 
Council and professional Societies: Romanian Society of 
Gastroenterology, Romanian Society of Microbiology. It is 
essential to ensure the traceability of supply, using a quality 
system. All activities related to stool banking should rely 
on the principals of good clinical practice and follow the 
recommendations of the European Council Guide to the Quality 
and Safety of Tissues and Cells for Human Application [133]. 
CONCLUSIONS
Fecal microbiota transplantation is an effective treatment 
for patients with rCDI, being an established treatment 
in many countries. This report provides guidance on the 
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general organization and the criteria required to perform 
FMT in patients with CDI. Despite sometimes with a low 
quality of evidence, a strong recommendation is recognized 
in considering the option of FMT for treatment of rCDI. 
This guideline should represent the scientific basis for FMT 
implementation in Romania. 
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